MacroGenics, Inc.
MGNXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. With a market capitalization of $280.3M, it sits in micro-cap territory. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Market Cap
$280.3M
Beta
1.23
P/E (TTM)
—
P/E (Fwd)
-3.00
EPS (TTM)
$-1.59
EPS (Fwd)
$-1.47
ROE
-225.9%
ROA
-8.1%
Cash
$173.3M
Total Debt
$35.1M
Free CF
-$69.4M
52W Change
154.3%
Annual Financials
Cash vs Debt
Where MGNX stands vs its 150-day and 200-day moving averages
As of the August 12, 2026 close, MGNX finished 21.74% above its 150-day moving average ($3.22) and 40.50% above its 200-day moving average ($2.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MGNX overbought or oversold?
At the August 12, 2026 close, MGNX's RSI(14) was 40.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $173.3M in cash comfortably exceeding the $35.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$69.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -225.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $150.0M (2022) to $149.5M (2025).
With cash comfortably exceeding debt, MGNX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MGNX.